Nirmish Shah, MD

Articles by Nirmish Shah, MD

Practice Pearls for the Management of SCD

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

November 9th 2022

A panel of experts in hematology discuss the future directions for sickle cell disease and share practice pearls for disease management.

Utility of Potential SCD Biomarkers in SCD Management

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

November 9th 2022

Matthew M. Heeney, MD, and Nirmish Shah, MD, hypothesize about the ability of emerging sickle cell disease biomarkers to assess risk-benefit and disease severity in patients.

Increasing Confidence in Emerging Therapies

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

November 9th 2022

Nirmish Shah, MD, and Matthew M. Heeney, MD, discuss the need for ongoing clinical trials and diversity in them to bolster data and improve provider confidence in emerging therapeutic options for sickle cell disease.

Role of Clinical Trial Endpoints and Metrics in SCD Therapies

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

November 2nd 2022

Dr Elna Saah highlights the role of data longevity, clinical trial end points, and metrics when evaluating novel treatments for the management of sickle cell disease.

Role of Gene Therapy in SCD Management

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

November 2nd 2022

Dr Matthew M. Heeney shares his hopes for the future of gene therapy in the management of patients with sickle cell disease.

Exploring Emerging Therapies and Their Potential for Curative Intent in SCD

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

October 26th 2022

Experts in hematology hypothesize about the potential for curative vs disease-modifying therapies in the management of sickle cell disease.

Current FDA-Approved Therapies for SCD Management

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

October 26th 2022

Matthew M. Heeney, MD, reviews the mechanism of action and the safety and efficacy data of FDA-approved therapies for the management of sickle cell disease.

Conversations Surrounding SCD Treatment Options

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

October 19th 2022

Nirmish Shah, MD, shares his advice for initiating conversations with patients about treatment options and selection criteria for sickle cell disease.

Exploring Patient-Reported Disease Burden and Unmet Needs

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

October 19th 2022

Nirmish Shah, MD; Elna Saah, MD; and Biree Andemariam, MD, highlight sickle cell disease burden through the lens of their patients and comment on unmet needs in disease management.

SCD: Unmet Needs, Prevalence, and Burden of Disease

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

October 12th 2022

An expert in hematology provides insight into the unmet needs, overall prevalence, and disease burden of sickle cell disease.

An Overview of Sickle Cell Disease (SCD)

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

October 12th 2022

Elna Saah, MD, provides an overview of sickle cell disease and comments on disease pathophysiology.

Impact of RBC Disorders on Patient QoL

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

October 5th 2022

Matthew M. Heeney, MD, leads a discussion on the impact of unhealthy RBCs and blood disorders on a patient’s quality of life.

Impact of Biochemical, Epigenetic, and Genetic Factors in RBC Health

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

October 5th 2022

Matthew M. Heeney, MD, and Elna Saah, MD, highlight the role of 2,3-disphosphoglycerate as well as epigenetic and genetic factors in RBC form and function.

Characteristics of an Unhealthy RBC

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

September 28th 2022

An expert in hematology provides an overview of the characteristics of an unhealthy RBC.

Role of Unhealthy RBCs in Blood Disorders

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

September 28th 2022

Dr Matthew M. Heeney reviews the characteristics of an unhealthy RBC and how they can lead to blood disorders.

Patient Conversations Regarding RBC Health

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

September 21st 2022

Biree Andemariam, MD, and Matthew M. Heeney, MD, comment on the importance of patient education in RBC health management and discuss how they initiate these conversations with patients.

Clinician Awareness of RBC Health and Related Laboratory Measurements

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

September 21st 2022

Dr Nirmish Shah shares his opinion surrounding the clinician awareness of RBC health metrics as well as diagnostic examinations, and Dr Elna Saah shares her insight into explaining these metrics to patients.

RBC Health Clinical Assessment

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

September 16th 2022

Dr Elna Saah leads a discussion on clinical and laboratory measures that can be utilized to determine RBC health.

Role of 2,3-disphosphoglycerate in RBCs

ByBiree Andemariam, MD,Nirmish Shah, MD,Elna Saah, MD,Matthew M. Heeney, MD

September 16th 2022

Matthew M. Heeney, MD, explores the role of 2,3-disphosphoglycerate in RBCs, highlighting the interplay of this compound with pyruvate kinase-R and hemoglobin.